2021년 2월 15일 09:47

GNT Pharma’s GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome

GNT Pharma today announced the Korea Animal and Plant Quarantine Agency (APQA) has approved the New Drug Application for GedaCure®, a chewable tablet of crisdesalazine, for the treatment of dogs with cognitive dysfunction syndrome (CDS) that suffe...

2020년 10월 15일 11:54

GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascular Thrombectomy

GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and efficacy of nelonemdaz in acute ischemic stroke patients treated with endovascular t...

2020년 1월 15일 09:06

GNT Pharma‘s Anti-dementia Drug ’crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia

GNT Pharma has successfully completed a Phase III clinical trial for crisdesalazine, a new drug for treating canine cognitive dysfunction syndrome or Alzheimer’s disease. In the clinical study conducted with 48 companion dogs with severe cognitive...